Fig. 2

The 4-lncRNA signature as a powerful predictor for OS and DFS of patients with NSCLC in the 3 cohorts. Patients with NSCLC were divided into high- and low-risk groups, based on the 4-lncRNA signature risk, and analyzed with Kaplan–Meier survival curves. Patients with high-risk had significantly worse OS (left panel) and DFS (right panel) in (a) the discovery cohort (n = 194), b the validation cohort (n = 172) and c the independent cohort (n = 73)